Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab
Arnon P. Kater,
Yanwen Jiang,
Brenda Chyla,
John F. Seymour
Affiliations
Arnon P. Kater
Department of Hematology, Amsterdam University Medical Centers, Location AMC, Amsterdam, on behalf of Hovon CLL Working Group, Amsterdam, the Netherlands
Yanwen Jiang
Genentech, Inc., South San Francisco, CA, USA
Brenda Chyla
AbbVie, North Chicago, IL, USA
John F. Seymour
Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia